Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$1.79 USD
+0.26 (16.99%)
Updated Sep 18, 2025 03:55 PM ET
After-Market: $1.80 +0.01 (0.56%) 5:12 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Humacyte, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
HUMA 1.79 +0.26(16.99%)
Will HUMA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Is It Worth Investing in Humacyte, Inc. (HUMA) Based on Wall Street's Bullish Views?
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Other News for HUMA
Humacyte (HUMA) Receives Consistent 'Buy' Rating from D. Boral Capital | HUMA Stock News
HUMA forms Bollinger Band Squeeze on September 17
Humacyte (HUMA) Reveals Promising Preclinical Study Results for CTEV
Humacyte announces preclinical data on CTEV use
Humacyte announces preclinical data on CTEV use